

2016 PQRS

Rheumatoid Arthritis Measures Group

Measures

- #108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- #128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
- #131 Pain Assessment and Follow-Up
- #176 Rheumatoid Arthritis (RA): Tuberculosis Screening
- #177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
- #178 Rheumatoid Arthritis (RA): Functional Status Assessment
- #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
- #180 Rheumatoid Arthritis (RA): Glucocorticoid Management
- #337 Tuberculosis Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier

Reporting Instructions

(1) Identify patients with the following criteria:

- Aged 18 years or older on the date of encounter
- Encounter during January 1 – December 31, 2016 with the following:

See Measures Specifications for Details

and

One of the following patient encounter codes:

99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, G0402

(2) Report all applicable measures within the measures group for at least 20 patients.

- The majority of the patients reported must be Medicare Part B Fee-for-service (FFS) patients, including Medicare Secondary and Railroad Medicare.
- For each measure, the measure's clinical performance must be satisfied for at least 1 patient. [Note: An asterisk (*) indicates that the measure's clinical performance is satisfied.]

For additional information or clinical rationale for measures, review the CMS Measure Specification for 2016 PQRS. All measures group Measure Specifications can be found on the NJII Member Portal > Registry > Getting Started section.

2016 PQRS

Rheumatoid Arthritis

Measures Group

Patient Information

First Name	Middle Initial	Last Name	Date of Birth	
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	
Visit Date	Medical Record Number	Gender	Male	Female
<input type="text"/>	<input type="text"/>	Medicare FFS Patient	Yes	No

Select Measures Performance

(page 1 of 4)

- * Recommended clinical performance satisfied
- ^ Patient is excluded from measure's performance

Select one (1) clinical action for each measure below, where applicable:

#108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Patients who were prescribed, dispensed, or administered at least one disease modifying anti-rheumatic drug (DMARD) during the measurement period

- DMARD prescribed, dispensed, or administered*
- Not prescribed (Medical reason documented)^
- Not prescribed (No reason documented)

#128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan

Patients with a documented BMI during the encounter or during the previous six months, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter

- BMI calculated as normal*
- BMI calculated as outside of normal range and follow-up documented*
- BMI not calculated (Patient not eligible)^
- BMI calculated as outside of normal range and follow-up NOT documented
- BMI not calculated (No reason documented)

Need more information? Connect with NJII PQRS Registry
973-642-4055 • pqrs@njii.com • www.njii.com/pqrs

Select Measures Performance

(page 2 of 4)

#131 Pain Assessment and Follow-Up

Patient visits with a documented pain assessment using a standardized tool(s) AND documentation of a follow-up plan when pain is present

Pain assessment documented as negative; no follow-up plan required*

Pain present and follow-up documented*

Pain assessment not performed, or pain assessment positive with no follow-up plan documented; patient not eligible (medical reason documented)^

Pain present and no follow-up documented

Pain assessment not documented (No reason given)

#176 Rheumatoid Arthritis (RA): Tuberculosis Screening

Patients for whom a TB screening was performed and results interpreted within 6 months prior to receiving a first course of therapy using a biologic DMARD

TB screening performed*

Not performed (Medical reason documented)^

Patient not receiving drug therapy

Not performed (No reason documented)

Measure not applicable

#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity

Patients with disease activity assessed by a standardized descriptive or numeric scale or composite index and classified into one of the following categories: low, moderate or high, at least once within 12 months

RA Disease Activity Assessed*

RA Disease Activity not Assessed

Select Measures Performance

(page 3 of 4)

#178 Rheumatoid Arthritis (RA): Functional Status Assessment

Patients for whom a functional status assessment was performed at least once within 12 months

Functional Status Assessed*

Functional Status Not Assessed

#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis

Patients with at least one documented assessment and classification (good/poor) of disease prognosis utilizing clinical markers of poor prognosis within 12 months

Disease prognosis assessed and classified*

Disease prognosis not assessed and classified

#180 Rheumatoid Arthritis (RA): Glucocorticoid Management

Patients assessed for glucocorticoid use and for those on prolonged doses of prednisone ≥ 10 mg daily (or equivalent) with improvement or no change in disease activity, documentation of a glucocorticoid management plan within 12 months

Patients not receiving glucocorticoid therapy*

Patient receiving < 10 mg daily prednisone (or equivalent); RA activity worsening; OR glucocorticoid use for < 6 months*

Patient receiving ≥ 10 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity and Glucocorticoid management plan documented*

Plan not documented (Medical reason documented)^

Plan not documented (No reason documented)

Select Measures Performance

(page 4 of 4)

#337 Tuberculosis Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier

Patients who have a documented negative annual TB screening or have documentation of the management of a positive TB screening test with no evidence of active tuberculosis, confirmed through use of radiographic imaging (i.e., chest x-ray, CT)

Documentation of negative or managed positive TB screen with further evidence that TB is not active*

No documentation of negative or managed positive TB screen^

Measure not applicable